218 related articles for article (PubMed ID: 35197393)
1. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
Fukushima J Med Sci; 2022 Apr; 68(1):1-10. PubMed ID: 35197393
[TBL] [Abstract][Full Text] [Related]
2. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.
Yokoyama S; Nakagawa C; Hosomi K
Support Care Cancer; 2022 Feb; 30(2):1765-1773. PubMed ID: 34595605
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
[TBL] [Abstract][Full Text] [Related]
6. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats.
Mansooralavi N; Khomula EV; Levine JD
Mol Pain; 2023; 19():17448069231185694. PubMed ID: 37338165
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
9. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D
Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
[TBL] [Abstract][Full Text] [Related]
12. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.
Hirayama Y; Ishitani K; Sato Y; Iyama S; Takada K; Murase K; Kuroda H; Nagamachi Y; Konuma Y; Fujimi A; Sagawa T; Ono K; Horiguchi H; Terui T; Koike K; Kusakabe T; Sato T; Takimoto R; Kobune M; Kato J
Int J Clin Oncol; 2015 Oct; 20(5):866-71. PubMed ID: 25762165
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.
Catalano M; Ramello M; Conca R; Aprile G; Petrioli R; Roviello G
Oncology; 2022; 100(7):384-391. PubMed ID: 35551139
[TBL] [Abstract][Full Text] [Related]
14. Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study.
Cohen SA; Veleber S; Siman J; Guthrie KA; McMillen K; Heit M; Wadhera S; Daniels J; Hansen K; Jacoby M; Taromina K; Chin S; Romeo M; Langley BO; Coveler AL; Hannan LM; King G; Purcell T; Safyan RA; Shankaran V; Zhen DB; Chiorean EG; Greenlee H
Contemp Clin Trials; 2023 Aug; 131():107273. PubMed ID: 37380021
[TBL] [Abstract][Full Text] [Related]
15. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
Battaglini E; Park SB; Barnes EH; Goldstein D
Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study.
Davis M; Loprinzi C
Support Care Cancer; 2022 Nov; 30(11):8845-8853. PubMed ID: 35953729
[TBL] [Abstract][Full Text] [Related]
17. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
18. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy.
Kuo A; Corradini L; Nicholson JR; Smith MT
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34202809
[TBL] [Abstract][Full Text] [Related]
20. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
